NCCN Guidelines® insights cancer-associated venous thromboembolic disease, version 2.2018 featured updates to the NCCN guidelines

201Citations
Citations of this article
166Readers
Mendeley users who have this article in their library.

Abstract

Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE.

Cite

CITATION STYLE

APA

Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Bockenstedt, P. L., Chesney, C., … Engh, A. M. (2018). NCCN Guidelines® insights cancer-associated venous thromboembolic disease, version 2.2018 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 16(11), 1289–1303. https://doi.org/10.6004/jnccn.2018.0084

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free